文献速递外周动脉疾病

VaSecure紫杉醇药物涂层球囊临床试验:一年结果

The VaSecure Paclitaxel Drug Coated Balloon Clinical Trial: One Year Outcomes.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2025-04-08

这项前瞻性多中心随机对照试验纳入199例慢性肢体威胁性缺血(CLTI)股腘动脉病变患者,1:1随机接受VaSecure紫杉醇药物涂层球囊(DCB)或标准经皮腔内血管成形术(PTA)。12个月随访显示两组全因死亡及截肢率无显著差异,DCB组主要不良事件、再狭窄、临床驱动靶病变血运重建(CD-TLR)及靶血管再干预(CD-TVR)率显著更低,一期通畅率显著更高。

要点

  • 12个月全因死亡(2.5% vs 1.3%)及截肢(0.0% vs 0.0%)两组无显著差异。
  • DCB组主要不良事件(7.5% vs 19.0%)、再狭窄(8.1% vs 19.0%)显著低于对照组。
  • DCB组12个月一期通畅率72.7% vs 50.0%,CD-TLR及CD-TVR(5.1% vs 15.0%)显著更优。

核心结论

  • VaSecure紫杉醇DCB与对照PTA在全因死亡及大/小截肢率方面安全性相当。
  • DCB组严重不良事件及主要不良事件率显著低于对照组。
  • DCB在12个月一期通畅率、再狭窄率、CD-TLR及CD-TVR方面疗效优于PTA。

研究设计与样本

  • 前瞻性多中心随机对照试验,16个中心纳入199例CLTI患者,1:1随机接受DCB血管成形术或PTA。
  • 全分析集199例;因40例关键数据缺失,符合方案集159例(DCB组80例 vs 对照组79例)。

主要发现

  • 12个月全因死亡2.5% vs 1.3%(p=1.0),大或小截肢0.0% vs 0.0%(p=1.0),靶血管血栓形成1.3% vs 0.0%(p=1.0)。
  • 6个月晚期管腔丢失DCB组0.38±0.58 vs PTA组1.25±1.13,差值-0.88(95%CI -1.16至-0.59),95%CI上限低于优效性阈值。
  • 6个月最小管腔直径DCB组3.15±1.14 vs PTA组2.30±1.29(p<.001)。
  • 12个月主要不良事件7.5% vs 19.0%(p=.032),一期通畅率72.7% vs 50.0%(p=.007),再狭窄8.1% vs 19.0%(p=.025),CD-TLR及CD-TVR 5.1% vs 15.0%(p=.025)。
  • 12个月踝肱指数变化DCB组0.63±0.22 vs PTA组0.51±0.25(p=.008),原文同时表述为两组间无统计学显著差异。

关键数值与推荐

  • 全因死亡2.5% vs 1.3%(p=1.0);大或小截肢0.0% vs 0.0%(p=1.0);靶血管血栓形成1.3% vs 0.0%(p=1.0)。
  • 6个月晚期管腔丢失0.38±0.58 vs 1.25±1.13,差值-0.88(95%CI -1.16至-0.59)。
  • 12个月主要不良事件7.5% vs 19.0%(p=.032);一期通畅率72.7% vs 50.0%(p=.007);再狭窄8.1% vs 19.0%(p=.025);CD-TLR及CD-TVR 5.1% vs 15.0%(p=.025)。

临床怎么用

  • 原文结论未据此给出具体临床推荐。

局限性

  • 原文报告因40例受试者关键数据缺失,符合方案集仅纳入159例(DCB组80例 vs 对照组79例)。
  • 原文指出该试验的两年和五年结果将在未来报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Previous randomised controlled trials (RCTs) have shown comparable short term outcomes of drug coated balloon (DCB) angioplasty vs. standard percutaneous transluminal angioplasty (PTA) in patients with chronic limb threatening ischaemia (CLTI) with femoropopliteal lesions. The study aimed to evaluate the one year follow up data of a multicentre RCT to verify the safety and efficacy of the VaSecure paclitaxel DCB vs. PTA for the treatment of femoropopliteal CLTI. METHODS: This prospective, multicentre RCT enrolled 199 subjects with CLTI from 16 centres. Subjects were randomised 1:1 to DCB angioplasty or PTA. Assessments through one year included freedom from clinically driven target lesion revascularisation (CD-TLR), amputation, and all cause death. Other outcomes assessed included risk factors for death and major amputation. RESULTS: The full analysis set included data for 199 subjects. Due to the absence of key data for 40 subjects, the per protocol set data included 159 subjects (DCB group, n = 80 vs. control group, n = 79). The intervention technical success and device success rates for both groups were 100%. There was no statistically significant difference between the two groups in rates of all cause death (2.5% vs. 1.3%; p = 1.0), major or minor amputation (0.0% vs. 0.0%; p = 1.0), target vessel thrombosis (1.3% vs. 0.0%; p = 1.0), and change in ankle brachial index (0.63 ± 0.22 vs. 0.51 ± 0.25; p = .008) at 12 month follow up. Late lumen loss at six months was 0.38 ± 0.58 in the DCB group and 1.25 ± 1.13 in the PTA group, with a difference of -0.88 (95% confidence interval [CI] -1.16 - -0.59). The upper limit of the 95% CI was below the threshold for superior efficacy. The minimum lumen diameter at six months was 3.15 ± 1.14 and 2.30 ± 1.29 in the two groups, respectively, with a statistically significant difference (p < .001). Rates of major adverse events (MAEs) (7.5% vs. 19.0%; p = .032), primary patency (72.7% vs. 50.0%; p = .007), re-stenosis (8.1% vs. 19.0%; p = .025), CD-TLR, and clinically driven target vessel re-intervention (CD-TVR) (5.1% vs. 15.0%; p = .025) at 12 months all showed statistically significantly better efficacy in the VaSecure paclitaxel DCB group compared with the control group. CONCLUSION: The results of this multicentre RCT showed comparable safety outcomes in all cause death and major or minor amputation rates for the VaSecure paclitaxel DCB and control groups. For the safety evaluation, the DCB angioplasty group had statistically significantly lower rates of severe adverse events and MAEs compared with the control group. Drug coated balloon angioplasty demonstrated superior effectiveness compared with PTA in primary patency, re-stenosis rate, CD-TLR, and CD-TVR at 12 months. Further results from this trial, including two and five year outcomes, will be reported in the future.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Shu C, Li X, Luo M, et al. The VaSecure Paclitaxel Drug Coated Balloon Clinical Trial: One Year Outcomes. Eur J Vasc Endovasc Surg. 2025. PMID: 40209853. doi:10.1016/j.ejvs.2025.04.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。